WallStSmart
BVS

Bioventus Inc

NASDAQ: BVS · HEALTHCARE · MEDICAL DEVICES

$9.87
+2.07% today

Updated 2026-04-30

Market cap
$682.47M
P/E ratio
30.58
P/S ratio
1.20x
EPS (TTM)
$0.33
Dividend yield
52W range
$6 – $11
Volume
0.4M

Bioventus Inc (BVS) Earnings

Quarterly earnings history, analyst estimates, and stock price reaction.

EPS beat streak
7 of 8
Last 8 quarters
Avg EPS surprise
+18.0%
Last 4 quarters
Revenue YoY growth
+2.8%
Most recent quarter
EPS YoY growth
+60.0%
Most recent quarter

Earnings surprise history (last 12 quarters)

Beat estimate Missed estimate

Quarterly EPS and revenue trend

Quarterly revenue EPS (diluted)

How the stock reacts to earnings

Avg 1-day reaction
+6.5%
Last 2 reports
Positive reaction rate
100%
2 of 2 quarters
Largest single-day move
+12.5%
2025-11-04
Report dateEPS actualSurpriseClose beforeClose after1-day reaction
2026-03-17$0.24+17.5%$8.87$8.92+0.6%
2025-11-04$0.15+36.4%$6.56$7.38+12.5%

Quarterly earnings history

Fiscal quarter endingEPS estimateEPS actualSurpriseRevenueYoY revenue
2025-12-31$0.20$0.24+17.5%$157.90M+2.8%
2025-09-30$0.11$0.15+36.4%$138.65M-0.2%
2025-06-30$0.21$0.21+0.0%$147.66M-2.4%
2025-03-31$0.02$-0.04-275.0%$123.88M-4.3%
2024-12-31$0.09$0.15+76.5%$153.64M+13.5%
2024-09-30$0.03$0.06+100.0%$138.96M+15.0%
2024-06-30$0.07$0.19+171.4%$151.22M+10.3%
2024-03-31$-0.07$0.07+200.0%$129.46M+8.7%
2023-12-31$0.02$0.07+250.0%$135.42M
2023-09-30$-0.02$0.05+350.0%$120.79M
2023-06-30$0.03$0.14+366.7%$137.07M
2023-03-31$-0.15$-0.26-73.3%$119.06M
2022-12-31$0.05$-0.06-220.0%

Frequently asked questions

Has Bioventus Inc beaten earnings estimates?
Bioventus Inc has beaten Wall Street EPS estimates in 7 of its last 8 quarterly reports, with an average EPS surprise of +18.0% over the last 3 quarters.
How does BVS stock react to earnings?
BVS stock has moved an average of +6.5% in the trading day following earnings over its last 2 reports, with positive reactions in 100% of those quarters.
What is Bioventus Inc's revenue growth rate?
Bioventus Inc reported year-over-year revenue growth of +2.8% in its most recent quarter, with EPS growing +60.0% year-over-year.